Analysts at one investment firm are already criticizing Thermo Fisher’s $3.2 billion bond offering announced yesterday, saying the move will likely increase the company’s debt load to risky levels. The scathing report was issued this morning by Gimme Credit, a fixed-income research firm, and followed news that Fitch Ratings had lowered the Waltham medical device giant’s credit rating by a notch to BBB and that Moody’s Investors Service said it probably will do the same once the bond sale closes. The Gimme Credit report questioned Thermo Fisher’s “ever-increasing appetite for debt” as the company works to raise the capital needed to complete its $13.6 billion acquisition of Carlsbad, Calif.-based Life Technologies.
Help employers find you! Check out all the jobs and post your resume.
